PRIME: The first 5 years

In 2016, the European Medicines Agency (EMA) launched the PRIority MEdicines (PRIME) scheme to provide early scientific and regulatory support for cutting-edge therapies with the potential to address unmet medical needs. Accelerating time-to-market enables patients to receive access to these types of medicines earlier, which can make a huge impact on their health and quality of life.   

During the first 5 years of the program, PRIME has accelerated the authorization of the first CAR T-cell therapies, vaccines, as well as novel gene therapies and cancer treatments. Recently, EMA has published a report analyzing the first years of the PRIME scheme, and the report shows that the program has made a positive impact. The report also identifies key areas for improvement and provides recommendations for optimizing PRIME to benefit even more patients in the future. 

Read more and download the full report: 

Athletes arrives at finish line on racetrack

Get in touch

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.